Helen Gnanapragasam 1 , Naghma Mustafa 1 , Mary Bierbrauer 1 , Tara Andrea Providence 1 , Paresh Dandona 1 Show Affiliations »
Abstract
CONTEXT AND OBJECTIVE: In spite of the evidence that inadequately controlled glycemia is associated with worse clinical outcomes, cystic fibrosis-related diabetes (CFRD) is not well controlled in a majority of patients. The objective of this report is to demonstrate the effect of the addition of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), to basal insulin to control glycemia in one such patient. DESIGN, INTERVENTION, AND THE MAIN OUTCOME MEASURES: The replacement of rapidly acting prandial insulin with semaglutide weekly with continuation of basal insulin. Glycated hemoglobin A1c (HbA1c) was measured and continuous glucose monitoring (CGM) was conducted. RESULTS: There was a significant improvement in glycemic control, reduction in HbA1c from 9.1% to 6.7% and stable euglycemic pattern on CGM (mean glucose, 142 mg/dL; SD, 51) within 3 months of starting treatment. There was no increase in plasma pancreatic enzyme concentrations. CONCLUSIONS: Semaglutide at a low dose was able to replace prandial insulin and control glycemia in combination with basal insulin. © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
CONTEXT AND OBJECTIVE: In spite of the evidence that inadequately controlled glycemia is associated with worse clinical outcomes, cystic fibrosis-related diabetes (CFRD) is not well controlled in a majority of patients . The objective of this report is to demonstrate the effect of the addition of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), to basal insulin to control glycemia in one such patient . DESIGN, INTERVENTION, AND THE MAIN OUTCOME MEASURES: The replacement of rapidly acting prandial insulin with semaglutide weekly with continuation of basal insulin . Glycated hemoglobin A1c (HbA1c) was measured and continuous glucose monitoring (CGM) was conducted. RESULTS: There was a significant improvement in glycemic control, reduction in HbA1c from 9.1% to 6.7% and stable euglycemic pattern on CGM (mean glucose , 142 mg/dL; SD, 51) within 3 months of starting treatment. There was no increase in plasma pancreatic enzyme concentrations. CONCLUSIONS: Semaglutide at a low dose was able to replace prandial insulin and control glycemia in combination with basal insulin . © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Entities: Chemical
Disease
Gene
Species
Keywords:
cystic fibrosis; diabetes; semaglutide
Mesh： See more »
Substances： See more »
Year: 2020
PMID： 32232400 DOI： 10.1210/clinem/dgaa167
Source DB: PubMed Journal: J Clin Endocrinol Metab ISSN： 0021-972X Impact factor: 5.958